Table 4.
Baseline characteristics for STEMI patients included in cardioprotection trials
| Age |
| Gender |
| Risk factors |
| Smoking |
| Comorbidities |
| Dyslipidemia |
| Hypertension |
| Diabetes mellitus |
| History of coronary artery disease |
| Previous MI |
| Preinfarction angina within 1 week before the index event |
| Infarct-related artery |
| Left anterior descending artery |
| Circumflex artery |
| Right coronary artery |
| Not identifiable |
| Number of other vessels with clinically significant disease |
| Symptom-to-balloon time |
| TIMI flow grade at admission |
| 0/I/II/III |
| Stenting of culprit lesion by pPCI |
| TIMI flow grade after procedure |
| 0/I/II/III |
| History of medication |
| Beta-blockers |
| Statins |
| ACE-inhibitors |
| AT-blockers |
| Calcium channel blockers |
| Long acting nitrates |
| Metformin |
| Insulin |
| Other antidiabetic drugs |
| Drugs given at time of pPCI |
| Heparin |
| Aspirin |
| P2Y12-inhibitors |